RenovoRx (NASDAQ:RNXT) Issues Quarterly Earnings Results, Beats Estimates By $0.02 EPS

Posted by George Bondi on Aug 14th, 2026

RenovoRx (NASDAQ:RNXT – Get Free Report) issued its quarterly earnings results on Wednesday. The company reported ($0.05) earnings per share for the quarter, topping the consensus estimate of ($0.07) by $0.02, FiscalAI reports. The business had revenue of $0.91 million during the quarter, compared to the consensus estimate of $0.70 million. RenovoRx had a negative return on equity of 138.07% and a negative net margin of 621.71%.

Here are the key takeaways from RenovoRx’s conference call:

Record revenue and upgraded guidance: Second-quarter revenue rose 61% sequentially and 115% year over year to $909,000, prompting RenovoRx to raise 2026 revenue guidance to $3.75 million–$4.25 million from $3 million–$4 million.
Commercial expansion is accelerating: Active commercial cancer centers increased from 16 to 21 during the quarter, with 42 additional centers in the pipeline and a target of at least 36 active centers by year-end. Management said repeat orders and site conversions from the TIGeR-PaC trial should support another record revenue quarter in Q3.
Clinical and product opportunity expanded: RenovoCath was used commercially for the first time in a sarcoma patient, providing physician-driven evidence of potential applications beyond locally advanced pancreatic cancer. Management also cited supportive clinical publications and growing physician advocacy.
Phase III trial enrollment completed: The TIGeR-PaC study is nearly fully randomized, with 78 of the required 86 events reported as of August 11, 2026. Trial completion is expected in the first half of 2027, with initial topline data anticipated in the second half of 2027.
Company remains loss-making and cash-constrained: RenovoRx reported a $3.4 million operating loss and held $9.5 million in cash at quarter-end. Although management expects cash to fund operations into the second half of 2027 and projects cash-flow break-even in Q4 2027, further capital could be needed if growth or trial timelines fall short.

RenovoRx Price Performance

RNXT stock traded up $0.06 during midday trading on Friday, hitting $1.32. 114,590 shares of the stock traded hands, compared to its average volume of 313,215. RenovoRx has a 1-year low of $0.70 and a 1-year high of $1.45. The stock’s fifty day simple moving average is $0.94 and its 200-day simple moving average is $0.94. The firm has a market cap of $59.42 million, a P/E ratio of -4.25 and a beta of 0.99.

Institutional Investors Weigh In On RenovoRx

Several hedge funds have recently modified their holdings of the company. XTX Topco Ltd increased its stake in shares of RenovoRx by 58.6% in the 4th quarter. XTX Topco Ltd now owns 50,140 shares of the company’s stock valued at $42,000 after purchasing an additional 18,525 shares in the last quarter. Northwestern Mutual Wealth Management Co. purchased a new position in RenovoRx during the second quarter worth approximately $98,000. Citadel Advisors LLC purchased a new position in RenovoRx during the third quarter worth approximately $154,000. Wealthspire Advisors LLC acquired a new stake in RenovoRx in the fourth quarter valued at approximately $212,000. Finally, Geode Capital Management LLC increased its position in shares of RenovoRx by 9.9% in the second quarter. Geode Capital Management LLC now owns 353,603 shares of the company’s stock valued at $467,000 after buying an additional 31,730 shares in the last quarter. 3.10% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on RNXT shares. Ascendiant Capital Markets raised their price target on shares of RenovoRx from $13.50 to $14.00 and gave the stock a “buy” rating in a report on Monday, June 1st. Weiss Ratings raised RenovoRx from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, July 17th. Finally, Wall Street Zen raised RenovoRx from a “strong sell” rating to a “sell” rating in a research report on Saturday, July 18th. One investment analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $8.50.

Read Our Latest Stock Analysis on RenovoRx

RenovoRx Company Profile

(Get Free Report)

RenovoRx, Inc is a clinical-stage medical technology company focused on the development of proprietary drug-device combination therapies for the treatment of solid tumor malignancies. The company’s lead product candidate, RenovoCath™, is an intra-arterial catheter system designed to deliver high concentrations of chemotherapeutic agents directly to tumor sites while minimizing systemic exposure. RenovoRx seeks to improve clinical outcomes and reduce adverse effects by enhancing drug delivery precision in hard-to-treat cancers.

RenovoCath™ is being evaluated in multiple clinical trials targeting advanced pancreatic cancer and metastatic colorectal cancer, among other solid tumors.